Hydrocortisone

Generic Name: Hydrocortisone

Brand Names: Ala-cort, Ala-scalp, Alcortin, Alkindi, Anusol HC, Aquanil HC, Casporyn HC, Cipro, Cipro HC, Colocort, Cortaid, Cortane-B, Cortef, Cortenema, Cortisporin, Cortizone-10, Dermacort, Dermarest Eczema, Dermazene, Home Papkit, Hydroskin, Monistat Itch Relief, Neosporin Eczema, Preparation H Hydrocortisone, Procto-med, Procto-pak, Proctocort, Proctol, Proctosedyl, Proctosol, Proctozone HC, Scalpicin Itch Relief, Texacort, Vanoxide-HC, Xerese, Plenadren, Efmody

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₃₀O_₅

CAS Number: 50-23-7

Unique Ingredient Identifier: WI4X0X7BPJ

Background: Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions. It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone.

Hydrocortisone was granted FDA approval on 5 August 1952.

Indication: Otic solutions are indicated for infections of the external auditory canal caused by susceptible organisms and with inflammation. Hydrocortisone tablets are indicated for certain endocrine, rheumatic, collagen, allergic, ophthalmic, respiratory, hematologic, neoplastic, edematous, gastrointestinal, and other conditions. A hydrocortisone enema is indicated for ulcerative colitis, a topical ointment with antibiotics is indicated for corticosteroid responsive dermatoses with infections, and a topical cream with acyclovir is indicated to treat cold sores. Oral granules of hydrocortisone are used as a replacement therapy for Adrenocortical Insufficiency (AI) in children under 17 years of age.

Associated Conditions: Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Adrenal Insufficiency, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Crohn's Disease (CD), Dermatitis, Dermatomyositis (DM), Dermatosis, Drug hypersensitivity reaction, Epicondylitis, Erythroblastopenia, Fissure;Anal, Haemorrhoids, Herpes Labialis, Hypercalcemia of Malignancy, Immune Thrombocytopenia (ITP), Infection of the Fenestration Cavity, Infection of the Mastoidectomy Cavity, Iridocyclitis, Iritis, Itching caused by Hemorrhoids, Itching of the Anus, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Lymphomas NEC, Mycosis Fungoides (MF), Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Hemorrhoids, Pemphigus, Posterior Uveitis, Posttraumatic Osteoarthritis, Primary adrenocortical insufficiency, Proctitis, Proteinuria, Pruritis of the skin, Psoriatic Arthritis, Rectal inflammations NEC, Rheumatic heart disease, unspecified, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Skin Diseases, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Trichinosis, Tuberculous Meningitis, Ulcerative Colitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Tenosynovitis, Acute rheumatic carditis, Anterior eye segment inflammation, Cryptitis, Disseminated Pulmonary Tuberculosis (TB), Exfoliative erythroderma, Fulminating Pulmonary Tuberculosis, Non-suppurative Thyroiditis, Severe Erythema multiforme, Severe Psoriasis, Subacute Bursitis, Superficial infection of the external auditory canal with inflammation, Symptomatic Sarcoidosis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: Palliative Treatment

Clinical Trials

The Effects of Propranolol, Hydrocortisone, and Morphine on Military-Relevant Performance Outcomes

Phase 4

Recruiting

Conditions: Fear of Spiders
Acute Stress Reaction

Interventions: Drug: Propranolol
Drug: Placebo (oral)
Drug: Hydrocortisone
Drug: Morphine
Drug: Placebo (IM)

First Posted Date: 2025-05-21

Last Posted Date: 2025-05-21

Lead Sponsor: Walter Reed Army Institute of Research (WRAIR)

Target Recruit Count: 110

Registration Number: NCT06982183

Locations: 🇺🇸
Sleep Research Center (SRC), Walter Reed Army Institute of Research, Silver Spring, Maryland, United States

Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation

Early Phase 1

Not yet recruiting

Conditions: CNS Embryonal Tumor
CNS, Medulloblastoma
Atypical Teratoid Rhabdoid Tumor
Medulloblastoma, Childhood
Medulloblastoma, Group 3
Medulloblastoma, Group 4
Pineoblastoma
Embryonal Tumor With Abundant Neuropil and True Rosettes
Ependymoblastoma
Medulloepithelioma

Interventions: Drug: Cytarabine IT
Drug: hydrocortisone
Drug: Cisplatin
Drug: Vincristine
Drug: Etoposide
Drug: Cyclophosphamide
Drug: Mesna
Drug: Filgrastim
Drug: carboplatin
Drug: Thiotepa
Drug: Topotecan IT
Drug: Tamoxifen
Drug: ISOtretinoin
Drug: Celecoxib
Drug: etoposide phosphate
Drug: Temozolomide

First Posted Date: 2025-04-24

Last Posted Date: 2025-04-24

Lead Sponsor: C17 Council

Target Recruit Count: 15

Registration Number: NCT06942039

Comparison Between Intravenous Hydrocortisone and Ondansetron in Prevention of Post Spinal Anesthesia Hypotension

Not Applicable

Conditions: Post Spinal Anaesthesia Hypotension

Interventions: Drug: hydrocortisone
Drug: ondansetron
Drug: Placebo

First Posted Date: 2025-04-16

Last Posted Date: 2025-04-16

Lead Sponsor: Nada kamel Elgamal

Target Recruit Count: 120

Registration Number: NCT06930456

Locations: 🇪🇬
Port Said Hospital, Port Said, Egypt

Intrathecal Cytarabine, Methotrexate, and Hydrocortisone for the Prevention of High-Grade Chimeric Antigen Receptor T-Cell-Associated Neurotoxicity Syndrome

Phase 2

Not yet recruiting

Conditions: Hematopoietic and Lymphatic System Neoplasm

Interventions: Procedure: Biospecimen Collection
Drug: Cytarabine
Procedure: Lumbar Puncture
Drug: Methotrexate
Drug: Therapeutic Hydrocortisone

First Posted Date: 2025-03-26

Last Posted Date: 2025-03-26

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 22

Registration Number: NCT06895473

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Comparing Hydrocortisone and Prednisolone for Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD)

Phase 4

Not yet recruiting

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Interventions: Drug: Hydrocortisone
Drug: Methylprednisolone (drug)

First Posted Date: 2025-03-25

Last Posted Date: 2025-03-30

Lead Sponsor: Copenhagen Respiratory Research

Target Recruit Count: 2000

Registration Number: NCT06892210

Comparing Hydrocortisone and Prednisolone for Community Acquired Pneumonia (CAP)

Phase 4

Not yet recruiting

Conditions: Community Acquired Pneumonia (CAP)

Interventions: Drug: hydrocortisone
Drug: Methylprednisolone (drug)

First Posted Date: 2025-03-25

Last Posted Date: 2025-03-30

Lead Sponsor: Copenhagen Respiratory Research

Target Recruit Count: 1600

Registration Number: NCT06892197

Effects of Intravenous Metabolic Recovery Agent in Elderly Septic Patients on Prognosis and Microcirculation.

Not Applicable

Recruiting

Conditions: Septic Shock

Interventions: Drug: Metabolic resuscitation agent
Drug: Hydrocortisone

First Posted Date: 2024-12-09

Last Posted Date: 2025-03-14

Lead Sponsor: Southeast University, China

Target Recruit Count: 40

Registration Number: NCT06723626

Locations: 🇨🇳
Zhongda Hospital Southeast University, Nanjing, Jiangsu, China

Effect of Early Hydrocortisone on Risk of Gastrointestinal Perforations in Extremely Preterm Infants

Active, not recruiting

Conditions: Intestinal Perforation

Interventions: Drug: Hydrocortisone

First Posted Date: 2024-07-23

Last Posted Date: 2024-10-03

Lead Sponsor: Imperial College London

Target Recruit Count: 16000

Registration Number: NCT06515405

Locations: 🇬🇧
Imperial College, London, United Kingdom

Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)

Phase 1

Recruiting

Conditions: Atopic Dermatitis

Interventions: Drug: ShA9 Topical Gel
Drug: Clobetasol Ointment
Drug: Hydrocortisone Ointment
Drug: Fluocinonide Ointment
Drug: Placebo (Vehicle) Topical Gel

First Posted Date: 2024-07-16

Last Posted Date: 2025-05-11

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 86

Registration Number: NCT06504160

Locations: 🇺🇸
University of California, San Diego: Dermatology Clinical Trials Unit, San Diego, California, United States
🇺🇸
National Jewish Health: Division of Pediatric Allergy and Clinical Immunology, Denver, Colorado, United States
🇺🇸
Northwestern University Feinberg School of Medicine: Department of Dermatology, Chicago, Illinois, United States

and more 5 locations

A Comparative Study of Glucocorticoids Efficacy in Acute Respiratory Distress Syndrome

Phase 2

Recruiting

Conditions: Acute Respiratory Distress Syndrome

Interventions: Drug: Methylprednisolone
Drug: Dexamethasone
Drug: Hydrocortisone

First Posted Date: 2024-07-11

Last Posted Date: 2025-01-06

Lead Sponsor: Fayoum University

Target Recruit Count: 300

Registration Number: NCT06496997

Locations: 🇪🇬
Fayoum University, Fayoum, Egypt

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy